Related Experiment Video
Updated: Jun 20, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Mycophenolate mofetil absorption quotient: interest to clinical practice
A Fernández1, J Villafruela, Y Amezquita
1Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain. afernandezr.hrc@salud.madrid.org
Abstract:
Use of mycophenolate mofetil (MMF) in kidney transplantation has led to significant improvements in the acute rejection index and graft survival. Posttransplant MMF levels are known to be of value for discriminating patients at risk of acute rejection. Trough MMF levels were measured in 153 patients who had undergone kidney transplantation more than 1 year before and showed stable graft function. MMF dosage was adjusted based on hematologic or gastrointestinal toxicity. The quotient between the weight-adjusted dose and through MMF levels was calculated in order to establish absorption type. We analyzed the diagnostic value of this quotient in relation to creatinine proteinuria, hematologic and gastrointestinal toxicity based upon percentiles of 10, 25, 50, 75, and 90, which were used as cutoff points. Mean MMF levels were 3.79 +/- 3.3 mg/L. Mean quotient value was 6.55 +/- 9.2. A significant correlation was found between MMF dosage and MMF trough levels (r = .34, P < .01). However, no correlation was seen between MMF dosage and the quotient. There were no significant differences in the analyzed parameters and the percentiles established as cutoff points. However, patients with gastrointestinal toxicity had a larger quotient (9.07 +/- 7.45.3 vs 5.28 +/- 4.9). The relationship between MMF dose and levels does not establish differences in kidney function and proteinuria among stable transplant patients; patients with diarrhea may show decreased absorption.
Insights
Mycophenolate mofetil (MMF) levels in kidney transplant patients correlate with dosage but not absorption. Gastrointestinal issues, like diarrhea, may indicate reduced MMF absorption in stable transplant recipients.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation medicine
Background:
- Mycophenolate mofetil (MMF) is crucial for improving acute rejection rates and graft survival in kidney transplantation.
- Monitoring post-transplant MMF levels aids in identifying patients at risk of acute rejection.
Purpose of the Study:
- To evaluate the diagnostic value of the quotient between weight-adjusted MMF dose and trough levels for assessing absorption in stable kidney transplant patients.
- To analyze the relationship between this quotient and clinical outcomes like creatinine, proteinuria, and toxicity.
Main Methods:
- Measured trough MMF levels in 153 stable kidney transplant recipients (>1 year post-transplant).
- Calculated the dose-to-level quotient to categorize absorption.
- Analyzed the quotient's correlation with creatinine, proteinuria, and gastrointestinal/hematologic toxicity using percentiles as cutoffs.
Main Results:
- A significant correlation was observed between MMF dosage and trough levels (r = .34, P < .01).
- No correlation was found between MMF dosage and the calculated absorption quotient.
- Patients experiencing gastrointestinal toxicity exhibited a significantly larger quotient (9.07 +/- 7.45 vs 5.28 +/- 4.9), suggesting potential absorption issues.
Conclusions:
- The MMF dose-to-level quotient does not reliably differentiate kidney function or proteinuria in stable transplant patients.
- Gastrointestinal toxicity, particularly diarrhea, may be associated with reduced MMF absorption in this population.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Factors Influencing Drug Absorption: Drug Dissolution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Hepatic Drug Clearance: Role of Transporters

